Proteomics

Dataset Information

0

Biosynthesis of novel non-proteinogenic amino acids β-hydroxyenduracididine and β-methylphenylalanine in Escherichia coli


ABSTRACT: Non-proteinogenic amino Q7 Q8 acids (npAAs) are valuable building blocks for the development of advanced pharmaceuticals and agrochemicals. The surge in interest in their synthesis is primarily due to the potential to enhance and diversify existing bioactive molecules. This can be achieved by altering these bioactive molecules to improve their effectiveness, reducing resistance compared to their natural counterparts or generating molecules with novel functions. Traditional production of npAAs in native hosts requires specialized conditions and complex cultivation media. Furthermore, these compounds are often found in organisms that challenge genetic manipulation. Thus, the recombinant production of these npAAs in a model organism like Escherichia coli paves the way for groundbreaking advancements in synthetic biology. For the first time, we report the synthesis of npAAs β-methylphenylalanine (BmePhe), β- hydroxyenduracididine (BhEnd), and enduracididine (End) from Streptomyces hygroscopicus in E. coli. Through proteomic and metabolomic analyses, we achieved the production of these compounds from two synthetic operons, comprising five heterologous proteins. Interestingly, we discovered that the exogenous addition of pathway precursors to the E. coli system enhanced the yield of BmePhe by 2.5 times, whereas it concurrently attenuated the production of BhEnd and End, signifying a selective precursor-dependent yield enhancement. The synthetic biology landscape is broadened in this study by expanding the repertoire of amino acids beyond the conventional set of 22 standard proteinogenic amino acids. The biosynthesized npAAs, End, BhEnd, and BmePhe hold promise for engineering proteins with modified functions, integrating into novel metabolites and/or enhancing biological stability and activity. Additionally, these amino acids’ biological production and subsequent purification present an alternative to traditional chemical synthesis methods, paving a direct pathway for pharmacological evaluation.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Escherichia Coli

SUBMITTER: Rosemary Gillane  

LAB HEAD: Esteban Marcellin

PROVIDER: PXD056235 | Pride | 2024-10-01

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
20220422_T3_003.raw Raw
20220422_T3_004.raw Raw
20220422_T3_005.raw Raw
20220422_T3_008.raw Raw
20220422_T3_009.raw Raw
Items per page:
1 - 5 of 26

Similar Datasets

2020-05-18 | GSE138044 | GEO
2009-08-25 | E-GEOD-17506 | biostudies-arrayexpress
| PRJEB35803 | ENA
2010-07-15 | E-MEXP-2796 | biostudies-arrayexpress
2021-07-21 | PXD022965 | Pride
2020-10-24 | E-MTAB-9677 | biostudies-arrayexpress
2010-09-02 | E-GEOD-23920 | biostudies-arrayexpress
2011-10-14 | E-GEOD-28630 | biostudies-arrayexpress
2022-10-20 | E-MTAB-12258 | biostudies-arrayexpress
2010-06-25 | E-GEOD-13219 | biostudies-arrayexpress